GSK’s Shingrix Shows Decade-Long Shingles Protection

GlaxoSmithKline plc (UK) (GB:GSK) has released an update.

GlaxoSmithKline plc reports that its Shingrix vaccine has proven to maintain high efficacy in preventing shingles in adults aged 50 and over for more than a decade. The final data from the phase III ZOSTER-049 trial showed a vaccine efficacy of 79.7% after six to 11 years, with no new safety concerns, bolstering confidence in long-term immunization strategies. This comes as a significant development given the risk shingles poses to adults as the immune system naturally declines with age.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.